Triple-drug combination therapy versus six-month proton pump inhibitor monotherapy in non-Helicobacter pylori Helicobacter eradication, and hyperacid environment preference of Helicobacter suis: a clinical study.
Proton Pump Inhibitors
/ administration & dosage
Humans
Helicobacter Infections
/ drug therapy
Drug Therapy, Combination
Male
Female
Middle Aged
Anti-Bacterial Agents
/ administration & dosage
Gastritis
/ drug therapy
Adult
Aged
Helicobacter heilmannii
/ isolation & purification
Helicobacter pylori
/ drug effects
Amoxicillin
/ administration & dosage
Clarithromycin
/ administration & dosage
Helicobacter
/ isolation & purification
Treatment Outcome
Gastric Mucosa
/ microbiology
Helicobacter suis
Eradication
Gender
Hyperacid environment.
Non-Helicobacter pylori Helicobacter
Proton pump inhibitor
Triple-drug combination therapy
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
28
08
2023
accepted:
30
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
epublish
Résumé
At present, eradication regimens for non-Helicobacter pylori Helicobacter (NHPH) have not been established yet. We investigated effectiveness of the standard triple-drug combination therapy for Helicobacter pylori eradication and of a proton pump inhibitor (PPI) monotherapy in eradication of NHPH. Subjects were the patients who were diagnosed with NHPH-infected gastritis based on microscopic findings, helical-shaped organisms obviously larger than Helicobacter pylori, in the gastric mucosal specimens using Giemsa staining at Kenwakai Hospital between November 2010 and September 2021, whose NHPH species were identified by polymerase chain reaction (PCR) analysis of urease genes in endoscopically-biopsied samples, and who consented to NHPH eradication with either the triple-drug combination therapy for one week or a PPI monotherapy for six months. Six months after the completion of eradication, its result was determined with esophagogastroduodenoscopy, microscopic examination, and PCR analysis. In cases of unsuccessful eradication, a second eradication with the other therapy was suggested to the patient. PCR analysis detected NHPH in 38 patients: 36 as Helicobacter suis and two as Helicobacter heilmannii/Helicobacter ailurogastricus. Fourteen Helicobacter suis-infected and one Helicobacter heilmannii/Helicobacter ailurogastricus-infected patients requested eradication therapy. The triple-drug combination therapy succeeded in four of five patients, while the PPI monotherapy succeeded in five of 10 patients. Three of five patients who had been unsuccessful with the latter therapy requested the triple-drug combination therapy as the second eradication and all three were successful. In total, the triple-drug combination therapy succeeded in seven out of eight (87.5%) attempted cases, while the PPI monotherapy in five out of 10 (50%) attempted cases. In NHPH eradication, the triple-drug combination therapy was considered to be effective to some extent and to become the first-line therapy. While, although less successful, PPI monotherapy appeared to be a potentially promising option particularly for patients with allergy or resistance to antibiotics. Effectiveness of PPI monotherapy may be attributed to hyperacid environment preference of Helicobacter suis and PPI's acid-suppressive effect. Additionally, male predominance in NHPH-infected gastritis patients may be explained by gender difference in gastric acid secretory capacity. However, further evidence needs to be accumulated. This study was approved by the Research Ethics Committee of Kenwakai Hospital (No. 2,017,024).
Sections du résumé
BACKGROUND
BACKGROUND
At present, eradication regimens for non-Helicobacter pylori Helicobacter (NHPH) have not been established yet. We investigated effectiveness of the standard triple-drug combination therapy for Helicobacter pylori eradication and of a proton pump inhibitor (PPI) monotherapy in eradication of NHPH.
METHODS
METHODS
Subjects were the patients who were diagnosed with NHPH-infected gastritis based on microscopic findings, helical-shaped organisms obviously larger than Helicobacter pylori, in the gastric mucosal specimens using Giemsa staining at Kenwakai Hospital between November 2010 and September 2021, whose NHPH species were identified by polymerase chain reaction (PCR) analysis of urease genes in endoscopically-biopsied samples, and who consented to NHPH eradication with either the triple-drug combination therapy for one week or a PPI monotherapy for six months. Six months after the completion of eradication, its result was determined with esophagogastroduodenoscopy, microscopic examination, and PCR analysis. In cases of unsuccessful eradication, a second eradication with the other therapy was suggested to the patient.
RESULTS
RESULTS
PCR analysis detected NHPH in 38 patients: 36 as Helicobacter suis and two as Helicobacter heilmannii/Helicobacter ailurogastricus. Fourteen Helicobacter suis-infected and one Helicobacter heilmannii/Helicobacter ailurogastricus-infected patients requested eradication therapy. The triple-drug combination therapy succeeded in four of five patients, while the PPI monotherapy succeeded in five of 10 patients. Three of five patients who had been unsuccessful with the latter therapy requested the triple-drug combination therapy as the second eradication and all three were successful. In total, the triple-drug combination therapy succeeded in seven out of eight (87.5%) attempted cases, while the PPI monotherapy in five out of 10 (50%) attempted cases.
CONCLUSIONS
CONCLUSIONS
In NHPH eradication, the triple-drug combination therapy was considered to be effective to some extent and to become the first-line therapy. While, although less successful, PPI monotherapy appeared to be a potentially promising option particularly for patients with allergy or resistance to antibiotics. Effectiveness of PPI monotherapy may be attributed to hyperacid environment preference of Helicobacter suis and PPI's acid-suppressive effect. Additionally, male predominance in NHPH-infected gastritis patients may be explained by gender difference in gastric acid secretory capacity. However, further evidence needs to be accumulated.
STUDY REGISTRATION
BACKGROUND
This study was approved by the Research Ethics Committee of Kenwakai Hospital (No. 2,017,024).
Identifiants
pubmed: 38720287
doi: 10.1186/s12876-024-03252-5
pii: 10.1186/s12876-024-03252-5
doi:
Substances chimiques
Proton Pump Inhibitors
0
Anti-Bacterial Agents
0
Amoxicillin
804826J2HU
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Clinical Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Informations de copyright
© 2024. The Author(s).
Références
Heilmann KL, Nowottny U. Histological demonstration of Campylobacter-like organisms in stomach biopsy. Dtsch Med Wochenschr. 1987;112:861–2. [Article in German].
pubmed: 3582194
Dent JC, McNulty CA, Uff JC, Wilkinson SP, Gear MW. Spiral organisms in the gastric antrum. Lancet. 1987;2:96.
doi: 10.1016/S0140-6736(87)92754-1
pubmed: 2885587
Stolte M, Kroher G, Meining A, Morgner A, Bayerdörffer E, Bethke B. A comparison of Helicobacter pylori and H. Heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol. 1997;32:28–33.
doi: 10.3109/00365529709025059
pubmed: 9018763
Kadota H, Yuge R, Miyamoto R, Otani R, Takigawa H, Hayashi R, et al. Investigation of endoscopic findings in nine cases of Helicobacter suis-infected gastritis complicated by gastric mucosa-associated lymphoid tissue lymphoma. Helicobacter. 2022;27(3):e12887.
doi: 10.1111/hel.12887
pubmed: 35363918
Okiyama Y, Matsuzawa K, Hidaka E, Sano K, Akamatsu T, Ota H. Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. Pathol Int. 2005;55:398–404.
doi: 10.1111/j.1440-1827.2005.01844.x
pubmed: 15982214
Yasuda T, Lee HS, Nam SY, Katoh H, Ishibashi Y, Murayama SY, et al. Non-Helicobacter Pylori Helicobacter (NHPH) positive gastric cancer. Sci Rep. 2022;12:4811.
doi: 10.1038/s41598-022-08962-y
pubmed: 35314746
pmcid: 8938428
O’Rourke JL, Solnick JV, Neilan BA, Seidel K, Hayter R, Hansen LM, et al. Description of ‘Candidatus Helicobacter heilmannii’ based on DNA sequence analysis of 16S rRNA and urease genes. Int J Syst Evol Microbiol. 2004;54:2203–11.
doi: 10.1099/ijs.0.63117-0
pubmed: 15545459
Abadi ATB, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. J Glob Antimicrob Resist. 2018;14:111–7.
doi: 10.1016/j.jgar.2018.03.005
Tsukadaira T, Hayashi S, Matsumoto T, Ota H. 2 cases of NHPH-gastritis that are thought to have been independently sterilized by PPI. Jpn J Helicobacter Res. 2017;18:21–7. [Article in Japanese].
Yoshimura M, Isomoto H, Shikuwa S, Osabe M, Matsunaga K, Omagari K, et al. A case of acute gastric mucosal lesions associated with Helicobacter heilmannii infection. Helicobacter. 2002;7:322–6.
doi: 10.1046/j.1523-5378.2002.00103.x
pubmed: 12390213
Ghysen K, Smet A, Denorme P, Vanneste G, Haesebrouck F, Van Moerkercke W. An atypical presentation of an acute gastric Helicobacter Feris infection. Acta Gastroenterol Belg. 2018;81:436–8.
pubmed: 30350536
Tsukadaira T, Hayashi S, Ota H, Kobayashi N, Sekiguchi Y, Kodaira H, et al. Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report. Helicobacter. 2021;26(4):e12814.
doi: 10.1111/hel.12814
pubmed: 33977610
Tsukadaira T, Hayashi S, Ota H, Kobayashi N, Sekiguchi Y, Kodaira H, et al. Prevalence, clinical features, and esophagogastroduodenoscopy findings of non-Helicobacter pylori Helicobacter infection: a study of 50 cases at a single facility in Japan. Helicobacter. 2021;26(4):e12811.
doi: 10.1111/hel.12811
pubmed: 33908121
Stolte M, Wellens E, Bethke B, Ritter M, Eidt H. Helicobacter heilmannii (formerly Gastrospirillum Hominis) gastritis: an infection transmitted by animals? Scand J Gastroenterol. 1994;29:1061–4.
doi: 10.3109/00365529409094888
pubmed: 7886392
Goldschmiedt M, Barnett CC, Schwarz BE, Karnes WE, Redfern JS, Feldman M. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterol. 1991;101:977–90.
doi: 10.1016/0016-5085(91)90724-Y
Iijima K, Ohara S, Koike T, Sekine H, Shimosegawa T. Gastric acid secretion of normal Japanese subjects in relation to Helicobacter pylori infection, aging, and gender. Scand J Gastroenterol. 2004;39:709–16.
doi: 10.1080/00365520410005911
pubmed: 15513353
Øverby A, Murayama SY, Michimae H, Suzuki H, Suzuki M, Serizawa H, et al. Prevalence of gastric Non-Helicobacter pylori-helicobacters in Japanese patients with gastric disease. Digestion. 2017;95:61–6.
doi: 10.1159/000452400
pubmed: 28052279
Shiratori S, Mabe K, Yoshii S, Takakuwa Y, Sato M, Nakamura M, et al. Two cases of chronic gastritis with non-Helicobacter pylori Helicobacter infection. Intern Med. 2016;55:1865–9.
doi: 10.2169/internalmedicine.55.5891
pubmed: 27432094
Goji S, Tamura Y, Sasaki M, Nakamura M, Matsui H, Murayama SY, et al. Helicobacter suis-infected nodular gastritis and a review of diagnostic sensitivity for Helicobacter Heimannii-Like Organisms. Case Rep Gastroenterol. 2015;9:179–87.
doi: 10.1159/000431169
pubmed: 26120299
pmcid: 4478311
Rimbara E, Suzuki M, Matsui H, Nakamura M, Morimoto M, Sasakawa C et al. Isolation and characterization of Helicobacter suis from human stomach. PNAS.2021;118(13):e2026337118.
Nakamura M, Øverby A, Michimae H, Matsui H, Takahashi S, Mabe K, et al. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori helicobacters in Helicobacter pylori-negative gastric disease patients in Japan: high susceptibility to an hp eradication regimen. Helicobacter. 2020;25(5):e12700.
doi: 10.1111/hel.12700
pubmed: 32790220
Nakamura M, Murasato F, Øverby A, Kodama Y, Michimae H, Sasaki K, et al. Effect of Acid suppressants on non–Helicobacter pylori Helicobacters within Parietal cells. Front Pharmacol. 2022;13:692437.
doi: 10.3389/fphar.2022.692437
pubmed: 35935877
pmcid: 9355715